Sequoia Financial Advisors LLC Acquires 1,646 Shares of Haleon plc (NYSE:HLN)

Sequoia Financial Advisors LLC grew its position in Haleon plc (NYSE:HLN) by 2.0% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 83,589 shares of the company’s stock after purchasing an additional 1,646 shares during the period. Sequoia Financial Advisors LLC’s holdings in Haleon were worth $881,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of the company. IMC Chicago LLC bought a new stake in shares of Haleon during the 1st quarter worth about $300,000. Wealth Enhancement Advisory Services LLC grew its holdings in Haleon by 42.5% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 66,247 shares of the company’s stock worth $562,000 after acquiring an additional 19,763 shares during the last quarter. Founders Financial Securities LLC bought a new stake in shares of Haleon in the 1st quarter valued at $552,000. Allspring Global Investments Holdings LLC bought a new stake in shares of Haleon in the 1st quarter valued at $43,000. Finally, Norden Group LLC boosted its stake in Haleon by 4,086.3% during the first quarter. Norden Group LLC now owns 428,129 shares of the company’s stock worth $3,635,000 after acquiring an additional 417,902 shares in the last quarter. 6.67% of the stock is currently owned by institutional investors and hedge funds.

Haleon Stock Down 0.5 %

NYSE:HLN opened at $9.84 on Friday. The firm’s 50-day moving average price is $10.23 and its 200-day moving average price is $9.19. The company has a market capitalization of $44.93 billion, a PE ratio of 32.80, a P/E/G ratio of 2.93 and a beta of 0.26. The company has a debt-to-equity ratio of 0.44, a current ratio of 0.84 and a quick ratio of 0.58. Haleon plc has a 1-year low of $7.70 and a 1-year high of $10.80.

Haleon (NYSE:HLN) last posted its earnings results on Thursday, August 1st. The company reported $0.08 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.01). Haleon had a net margin of 9.71% and a return on equity of 13.15%. The company had revenue of $3.50 billion for the quarter, compared to the consensus estimate of $3.55 billion. During the same quarter in the prior year, the company posted $0.08 EPS. On average, equities analysts predict that Haleon plc will post 0.47 EPS for the current fiscal year.

Haleon Cuts Dividend

The firm also recently announced a semi-annual dividend, which was paid on Thursday, September 19th. Stockholders of record on Friday, August 16th were given a dividend of $0.0514 per share. The ex-dividend date of this dividend was Friday, August 16th. This represents a dividend yield of 1.6%. Haleon’s dividend payout ratio (DPR) is 33.33%.

Analysts Set New Price Targets

HLN has been the topic of several research reports. The Goldman Sachs Group downgraded shares of Haleon from a “buy” rating to a “neutral” rating in a report on Tuesday, August 6th. Morgan Stanley increased their target price on shares of Haleon from $9.90 to $10.95 and gave the stock an “overweight” rating in a research report on Friday, September 20th. Berenberg Bank started coverage on shares of Haleon in a research report on Tuesday, August 6th. They set a “buy” rating for the company. Finally, UBS Group raised shares of Haleon to a “strong-buy” rating in a research note on Tuesday, October 1st. One equities research analyst has rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $10.95.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.